Sign Up for a Free Account
  • Updated 06.04.2021
  • Released 12.02.2003
  • Expires For CME 06.04.2024

Memantine

Introduction

Historical note and terminology

Memantine hydrochloride was originally synthesized in 1963 at Eli Lilly & Co as an antidiabetic agent but was found to be ineffective in lowering elevated blood sugar. Merz & Co in Germany took it over and, a decade later, showed its effectiveness in Parkinson disease. In 1989, therapeutic action of memantine was shown to be due to antagonism of N-methyl-D-aspartate receptors (11), and it was launched in Germany for the treatment of dementia. Further clinical trials were conducted on its use in Alzheimer disease between 1995 and 2000, and the drug was approved in the European Union in 2002. The FDA approved it for the treatment of moderate to severe Alzheimer disease in 2003. It is marketed in the United States under the trade name of “Namenda” (Forest Laboratories).

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, 
including video clips of 
neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of 
neurology in 1,200 
comprehensive articles.

Questions or Comment?

MedLink, LLC

10393 San Diego Mission Rd, Suite 120

San Diego, CA 92108-2134

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com